/publications/issue/2008/2008-12/2008-12-5029

Rx Product News

Author:

Tetrix Cream

Marketed by:
Coria Laboratories Ltd (Fort Worth, TX)

Indication:
October 24, 2008—Coria Laboratories Ltd announced that it introduced Tetrix Cream, the first prescription protection for the treatment of hand eczema and hand dermatitis, which is estimated to affect as many as 25 million Americans. Tetrix Cream is a nonsteroidal cream comprised of aluminum magnesium hydroxide stearate, cetyl dimethicone copolyol, cyclomethicone, dimethicone, hexyl laurate, polyglyceryl-4-isostearate, purified water, and sodium chloride. It also contains phenoxyethanol and propylparaben as preservatives. The cream may be applied 2 to 3 times a day or as prescribed.

Dosage Form:
Supplied in a kit including two 2-oz tubes with 2 complimentary 2-oz tubes of CeraVe Cream.

For More Information:
www.corialabs.com
www.TetrixCream.com
866-819-9007


Afluria

Marketed by:
CSL Biotherapies (King of Prussia, PA)

Indication:
September 4, 2008—CSL Biotherapies announced that it began shipment of Afluria (influenza virus vaccine), in the United States for the 2008-2009 influenza season. Afluria is indicated for the active immunization of individuals aged 18 years and older against influenza disease caused by influenza virus subtypes A and type B. CSL plans to deliver more than 6 million doses of Afluria, and the majority of the supply will be in single-dose, thimerosal- free, prefilled syringes. Afluria was originally granted marketing approval by the FDA on September 28, 2007. CSL Biotherapies also announced an innovative online, quick-ship ordering system, enabling health care providers and other purchasers to buy Afluria for adults directly from the company. The new purchasing platform is available at www.mercuryfreefluvaccine.com.

Dosage Form:
0.5-mL, preservative-free, single-dose, prefilled syringe; 5-mL multidose vial containing 10 doses

For More Information:
www.Afluria.com
888-435-8633



Astepro

Marketed by:
Meda Pharmaceuticals Inc (Somerset, NJ)

Indication:
October 17, 2008—Meda Pharmaceuticals Inc, the US subsidiary of Meda AB, announced that the FDA approved Astepro (azelastine hydrochloride)—the new formulation of Astelin. Astepro Nasal Spray is an improvement over the marketed Astelin Nasal Spray and is better tolerated by patients using the new spray. The active substance in these products is azelastine— the leading nasal antihistamine in the treatment of rhinitis in the United States. Astepro is now approved for the treatment of seasonal allergic rhinitis.

Dosage Form:
137 mcg per spray

For More Information:
www.medpointepharma.com



Forteo

Marketed by:
Eli Lilly and Co (Indianapolis, IN)

Indication:
October 16, 2008—Eli Lilly and Co announced that its new, simpler-to-use Forteo (teriparatide [rDNA origin] injection) Delivery Device is available for patient use in the United States. The new delivery device was designed specifically for Forteo patients to help them more easily administer their treatment on a day-to-day basis. Originally approved by the FDA in June, the new delivery device is now being shipped to pharmacies and will be available for patients when they fill their prescriptions. Forteo is indicated for the treatment of osteoporosis in postmenopausal women who are at high risk for fracture and to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.

Dosage Form:
20 mcg once daily

For More Information:
www.FORTEO.com



Rapaflo

Marketed by:
Watson Pharmaceuticals Inc (Corona, CA)

Indication:
October 8, 2008—Watson Pharmaceuticals Inc announced that the FDA approved Rapaflo (silodosin), the company's new alpha-blocker for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH). BPH is the number-1 reason patients visit urologists and is characterized by urination problems, including decreased urine flow, more frequent urination, and nocturia. Rapaflo is an effective, selective alpha-1 adrenergic receptor antagonist.

Dosage Form:
Capsules: 4 and 8 mg

For More Information:
www.watson.com



Reyataz

Marketed by:
Bristol-Myers Squibb Co (Princeton, NJ)

Indication:
October 1, 2008—Bristol-Myers Squibb Co announced that the FDA approved the use of Reyataz (atazanavir sulfate) 300 mg once-daily boosted with ritonavir 100 mg as part of combination therapy in previously untreated (treatment-na?ve) HIV- 1?infected patients. Reyataz is a protease inhibitor used in combination with other antiretroviral agents to treat individuals who are infected with HIV. Reyataz boosted with ritonavir taken once daily with food is recognized by the US Department of Health and Human Services as a preferred component of combination HIV therapy for treatment-na?ve patients.

Dosage Form:
Capsules: 100, 150, 200, and 300 mg

For More Information:
www.reyataz.com
www.BMS.com


Find it Online

For more Rx Product News, visit www.PharmacyTimes.com/Rxproducts